European Organisation For Research & Treatment Of Cancer
🇬🇧United Kingdom
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Not Applicable
Not yet recruiting
- Conditions
- Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 50
- Registration Number
- NCT06990061
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
Phase 1
Not yet recruiting
- Conditions
- GastroEsophageal Cancer
- Interventions
- Drug: FLOT
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-06-05
- Target Recruit Count
- 27
- Registration Number
- NCT06978062
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3
Not yet recruiting
- Conditions
- IDH-mutant Grade 2 or 3 Astrocytoma
- Interventions
- Drug: Vorasidenib Placebo
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 468
- Registration Number
- NCT06809322
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Kepler University Hospital - Neuromed campus, Linz, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-23
- Target Recruit Count
- 48
- Registration Number
- NCT06783348
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
Not Applicable
Not yet recruiting
- Conditions
- Colorectal CancerProstate CancerOligometastatic DiseaseBreast CancerNSCLC
- Interventions
- Radiation: multiple-fraction SBRTRadiation: single-fraction SBRT
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-02-26
- Target Recruit Count
- 302
- Registration Number
- NCT06462963
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- ER+ Breast CancerHER2-negative Breast CancerBreast Cancer Stage IIIBreast Cancer Stage IDrug-Related Side Effects and Adverse ReactionsMusculoskeletal PainBreast Cancer Stage II
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 399
- Registration Number
- NCT06407401
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
Not Applicable
Not yet recruiting
- Conditions
- Head and Neck Neoplasms
- Interventions
- Procedure: Early palliative care, integrated with the standard oncologic care (proactive approach)Procedure: Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Target Recruit Count
- 160
- Registration Number
- NCT06347185
177Lu-DOTATATE for Recurrent Meningioma
Phase 2
Recruiting
- Conditions
- Recurrent Meningioma
- Interventions
- Drug: Local standard of Care
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-06-23
- Target Recruit Count
- 135
- Registration Number
- NCT06326190
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭Oncology Institute of Southern Switzerland (IOSI) - Ospedale San Giovanni, Bellinzona, Switzerland
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
Phase 2
Not yet recruiting
- Conditions
- Bladder Cancer
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 50
- Registration Number
- NCT06310369
Adjuvant Tebentafusp in High Risk Ocular Melanoma
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-06-23
- Target Recruit Count
- 290
- Registration Number
- NCT06246149
- Locations
- 🇪🇸
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), Hospitalet de Llobregat, Spain
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇫🇷Institut Curie - Hôpital de Paris, Paris, France